We have unexpectedly found that Streptomyces subtilisin inhibitor (SSI) and some other similar serine protease inhibitors produced by Streptomycetes strongly inhibit Streptomyces griseus metallo-endopeptidase II (SGMP II) [Kajiwara, K. et aL (1991) J. Biochem. 110, 350-354]. In order to elucidate the mode of their unusual interaction with SGMP II in more detail, we prepared twelve kinds of SSI analogues, in which one or two amino acid residues in the peptide segment from Thr64 to Val74 of wild-type SSI had been replaced or deleted by site-directed mutagenesis, and determined the dissociation constants of their complexes with SGMP II. Six analogues among them showed dissociation constants one order of magnitude lower than that of the wild type. Three had higher values. The results suggest that at least some residues in this segment are interacting with SGMP II in the complex. We also prepared an SSI mutant in which the disulfide bridge between Cys71 and CyslOl had been eliminated by replacing the two Cys residues with Ser residues. This mutated SSI inhibited SGMP II as strongly as the wild-type SSI did. While peptide bonds in the wild-type molecule did not suffer from the hydrolytic action of SGMP II except those at the amino-terminal fragile portion, the Pro72-Met73 bond of the mutant was specifically cleaved by the enzyme. This peptide bond, therefore, seems to play the role of the reactive site in the interaction of SSI with SGMP II.
Streptomycetes produce a variety of protease inhibitors, such as Streptomyces subtilisin inhibitor (SSI) (2), plasminostreptin (PS) (2) , alkaline protease inhibitor-2c' (API-2c') (3), and Streptomyces metallo-protease inhibitor (SMPI) (4) . The former three are inhibitors of serine proteases and the last is an inhibitor of metallo-proteases. All of them are proteins, and their amino acid sequences have been determined {5-8) . Chemical and physical studies on SSI, the best studied among them, have been reviewed (9) . SSI is a dimer (M r 23,000) composed of identical subunits and forms a stable 2:2 complex with subtilisin BPN'. PS and API-2c' are analogous to SSI. The main difference among them is in their inhibitory specificities. The reactive site of SSI for subtilisin BPN' has been identified as the Met73-Val74 bond (10) , and the mode of their molecular interaction has been elucidated by X-ray crystallography (11) (12) (13) .
One of the authors (S.I.) and his coworkers have previously found that SSI can inhibit Streptomyces griseus serine 1 To whom correspondence should be addressed. "Present address: Central Research Laboratories, Ajinomoto Co., Inc., 1-1 Suzuki-cho, Kawasaki-ku, Kawasaki 210. Abbreviations: API-2c', alkaline protease inhibitor-2c'; Bim, 1,7-dioxo-2,5,6-trimethyl-l/f,7H-pyrazolo[l,2-a]pvrazol-3-yl-methyl-; HPLC, high-performance liquid chromatography; BES, N,N-bis(2-hydroxyethyl)-2-aminosulfonicacid; PTH, phenylthiohydantoin; PS, plasminostreptin; SGMP I and SGMP n, Streptomyces griseus metallo-endopeptidases I and II; SGPA and SGPB, Streptomyces griseus (serine) proteases A and B; SMPI, Streptomyces metalloprotease inhibitor; SSI, Streptomyces subtilisin inhibitor; TFA, trifluoroacetic acid.
proteases A and B (SGPA and SGPB) as strongly as subtilisin BPN ' (14) . The findings indicated that the targets of SSI are not restricted to serine proteases of the subtilisin family, because SGPA and SGPB belong to the chymotrypsin family. We, therefore, decided to reinvestigate the specificity of SSI and other serine protease inhibitors produced by Streptomycetes, in view of their physiological functions.
Tsuyuki et at. have isolated two metallo-endopeptidases, SGMP I and SGMP II, from Pronase P, which is a protease mixture produced by S. griseus (15) . The two enzymes were distinguishable only in their behavior on ion-exchange chromatography. Both of them were found to contain 1 g atom of Zn per mol (M r 37,000), and their activities were sensitive to metallo-protease inhibitors, such as o-phenanthroline, phosphoramidon, and SMPI. Remarkable findings are that these "metalloproteases" were strongly inhibited by SSI, PS, and API-2c' which had been classified as "serine protease" inhibitors (25) . The mode of this unusual inhibition has been examined, and the results may be summarized as follows: (i) dissociation constants of the complexes of SGMP II with these inhibitors range from nM to pM order; (ii) an SSI dimer binds two molecules of SGMP II, as is the case with subtilisin BPN'; (iii) SGMP II and subtilisin BPN' interact with SSI in a competitive manner. On the basis of these results, we speculated that the area on an SSI molecule responsible to the interaction for SGMP II would overlap with that for subtilisin BPN' (26) . However, the reactive site of SSI for SGMP II has not been assigned yet.
Recently the SSI gene was cloned and an expression system was established {17). Furthermore, various SSI analogues were prepared by site-directed mutagenesis to elucidate the functional role of amino acid residues of the inhibitor molecule in the binding with serine proteases (18, 19) . These studies demonstrated that the potency and specificity of SSI as an inhibitor of serine proteases could be altered by replacing the PI (Met73) and P4 (Met70) site residues [after the Schechter and Berger notation (20) ] in the reactive site region.
In this study, we compared the inhibitory activity of SSI towards SGMP II with those of various mutated SSIs which contained replacement or deletion at one or two residues in the peptide segment from Thr64 to Val74, near the reactive site for subtilisin BPN'. Furthermore, a disulfide-bridgeeliminated SSI mutant, SSI(C71S, C101S), was examined for susceptibility to the proteolytic action of SGMP II and the target of the action was investigated. On the basis of the results, we will discuss the reactive site of SSI for SGMP II.
MATERIALS AND METHODS
Materials-Wild-type SSI was a gift from Prof. S. Murao of the Kumamoto Institute of Technology. Various SSI genes were prepared by site-directed mutagenesis and expressed in Streptomyces lividans, and the excreted SSI protein was purified as previously described (17) . Mutated SSIs used in this study are listed in Table I . The purity of each of them was checked by amino acid composition analysis after acid hydrolysis. SGMP II and SGPB were prepared from Pronase P according to the reported methods (15, 21, 22) . a-Chymotrypsin was purchased from Sigma Chemical. Subtilisin BPN' was obtained as a gift from Prof. B. Tonomura of Kyoto University. Intramolecularly quenched bimane-peptide substrates such as Bim-SCH 2 CO-Phe-Trp-Leu-OH and Bim-SCH 2 CO-Gly-TrpLeu-OH were prepared by Dr. E. Sato as previously described (23) .
Determination of Concentrations of Enzymes and Protease Inhibitors-Concentrations of SGMP II, subtilisin BPN', SGPB, and a-chymotrypsin were spectrophotometrically determined as previously described (15) . Molar concentrations (as monomer) of wild-type SSI and mutant SSIs were determined by amino acid composition analysis after acid hydrolysis.
Measurement of Equilibrium Dissociation Constants (KJ-Prior to the determination of K, values, association rate constants (fen) of the reaction between mutated SSIs and SGMP II were estimated under pseudo first order conditions in the presence of Bim-SCH 2 CO-Phe-Trp-Leu-OH, as previously described (16) . The fe n values thus obtained were used for the estimation of a time sufficient to establish the equilibrium. For the measurement of K\ values, mixtures of SGMP II with various concentrations of a mutated SSI were incubated at 25'C in 25 mM BESNaOH, pH 7.0, containing 3 mM CaCl 3 , 90 mM NaCl, and 0.1% polyethyleneglycol 6000 for a time sufficient to establish equilibrium (1-6 h). To the equilibrium mixture, a small volume of a suitable bimane-peptide substrate (0.27 //M final concentration) was added, and the residual activities were measured fluorometrically (16, 24) . The enzyme concentration was as follows: 0.1 nM for SSI (M73F), SSI(M73G), SSI(M73P), SSI(M73K), SSI(M70G, M73K), and SSI(V74I); 0.25 nM for SSI(C71S, C101S); 5.7 nM for SSI(T64d), SSI(G66zJ), and SSI(T64zJ, 8.0 nM for SSI(M70G), SSI(M70A). The residual enzyme activity was plotted against the inhibitor concentration. The K, values were estimated by the non-linear regression analysis of Sakoda and Hiromi (25) .
Limited Proteolysis of a Disulfide-Bridge-Eliminated SSI Mutant, SSI(C71S, C101S), with SGMP Z7-SSI (C71S, C101S) (34//M) was incubated at 0-1'C with SGMP H (0.34 fiM) in 20 mM Tris-HCl, pH 7.5, containing 2 mM CaCl 2 for up to 6 h. Aliquots of the reaction mixture were withdrawn at intervals and subjected to reversedphase HPLC on a column (4.6 X 75 mm) of Ultrapore RPSC (Beckman Instruments). Elution was carried out with a linear gradient of acetonitrile in 0.1% TFA. The effluent was monitored by measuring the absorbance at 210 ran. Cleavage products, after separation by HPLC, were subjected to amino acid composition analysis and sequence analysis.
Amino Acid Composition Analysis and Sequence Analysis-Peptides were hydrolyzed with 6 M HC1 containing 0.05% phenol in evacuated and sealed tubes at 110'C for 24 h. The amino acids were analyzed as phenylthiocarbamoyl derivatives (26) on an Applied Biosystems Model 130A Separation System. For the analysis of mutated SSIs, a Hitachi 835 amino acid analyzer equipped with a ninhydrin reactor was used. The amino acid sequence of peptides was determined on an Applied Biosystems Model 477A/120A Protein Sequencer/PTH Analyzer System.
RESULTS

Equilibrium Dissociation Constants (KJ of the SGMP II-Mutated SSI
Complexes-In the previous study (16) we obtained several lines of evidence showing that the interacting area on an SSI molecule for SGMP II overlaps with that for subtilisin BPN'. X-ray crystallographic analysis showed that the reactive site loop involving a segment from Thr64 to Val74 plays a central role in the interaction with subtilisin BPN' (11) (12) (13) . We tried, therefore, to examine the effects of amino acid replacement or deletion in this segment on the strength of interaction with SGMP II to confirm the previous observations. Thirteen mutated SSIs were prepared by site-directed mutagenesis and the K, values were determined. The results are summarized in Table I , in which the mutation sites are also shown. All the values were in the nM range. SGMP II showed the following preference for the residue at position 73, which corresponds to the PI site toward subtilisin BPN': Pro>Met (wild-type) >Gly >Lys>Phe. Substitution of Met70 with smaller residues such as Gly and Ala strengthened the enzyme-inhibitor interaction markedly (6-and 9-fold, respectively). Conversion of SSI(M73K) to SSI(M70G, M73K) also resulted in a 4-fold increase in the affinity. Replacement of Asp68 with Asn or deletion of Thr64 and/ or Gly66 also increased the affinity (5-10-fold). On the other hand, replacement of Val to He at position 74 did not have any effect on the interaction. From these findings we may estimate that at least the segment of Thr64-Met73 in SSI is involved in the interaction with SGMP n, if the mutation does not induce a considerable structure change of the SSI molecule.
Limited Proteolysis of a Disulfide-Bridge-Eliminated SSI Mutant, SSI(C7lS, C101S), with SGMP II-Our first CaClj for up to 6 h. Aliquots of the reaction mixture were withdrawn at intervals and analyzed on reversed-phase HPLC using a column (4.6x75 mm) of Ultrapore RPSC (Beckman Instruments). Elution was carried out with a 3-min linear gradient of 1-13% acetonitrile in 0.1% TFA, followed by a 27-min linear gradient of 13-33% acetonitrile in 0.1% TFA at a flow rate of 1 ml/min. The effluent was monitored by measuring the absorbance at 210 nm. The two newly formed peaks, MP-1 and MP-2, were separately pooled and subjected to peptide analysis as described in "MATERIALS AND METHODS.' effort to detect the reactive site of SSI for SGMP II was unsuccessful, because the wild-type SSI was not cleaved by SGMP II at a specific peptide bond (16) . The problem was overcome by the use of SSI(C71S, C101S) instead. As 1 ). Note that the sum of the peak areas [MP-1 + MP-2 + intact SSI] was always equal to the peak area of the initial SSI for up to 6 h, which indicated that only limited proteolysia occurred.
already shown in Table I , the inhibitory activity of this SSI mutant toward SGMP II was almost the same as that of wild-type SSI. Kojima et al observed that the inhibitory activity of this mutant toward subtilisin BPN' gradually decreased during the incubation. This was due to enzymatic degradation of the mutant SSI through a specific intermediate formed by cleavage at the reactive site peptide bond (Met73-Val74) (27) . We also observed that other serine proteases such as a -chymotrypsin and SGPB, both of which had been shown to be inhibited by wild-type SSI, were able to cleave this mutant initially at the Met73-Val74 bond (data not shown). We expected that the mutant SSI would easily undergo limited proteolysis also with SGMP II as well. SSI(C71S, C101S) was incubated with a catalytic (5) . SSI(C71S, C101S) secreted from Streptomyces lividans 66 has been reported to contain a three-amino-acid extension (Ala-ProGly) at the amino terminus (38) , and so these residues are added to the sequence data.
b Not determined. c Determined as the sum of methionine and methionine sulfoxide contents. amount of SGMP II under various conditions, and the time course was monitored by reversed-phase HPLC. Typical HPLC-patterns of the digests at pH 7.5 and 0-l°C are illustrated in Fig. 1 . Two peaks, MP-1 and MP-2, appeared and the peak areas steadily increased. Similar product patterns were observed at 15 and 3TC, but under these conditions, particularly at 37"C, many peaks due to cleavage at additional sites appeared during prolonged incubation (data not shown). Figure 2 shows a time course of formation of the modified inhibitor (MP-1 + MP-2). The formation reached a plateau at 5-6 h at pH 7.5 and 0-1'C. The effect of pH on the rate of this limited proteolysis was then examined at 0-1'C in the range from pH 3 to 10. The optimum pH was around 7. The specific cleavage occurred between pH 6 and 10, and rapid and non-specific degradation proceeded between pH 4.5 and 5.5. The reasons for the non-specific cleavage are unknown. Below pH 4, SGMP II hardly cleaved this mutant SSI.
To determine the site of specific cleavage, MP-1 and MP-2 were separately pooled and subjected to amino acid composition and amino-terminal sequence analyses (Tables  II and HI) . The compositions of MP-1 and MP-2 correspond to residues 73-113 and -3-72, respectively [on the numbering of SSI(C7lS, C101S); see Table II ]. The sequence data also indicated that SGMP II had cleaved the SSI mutant at a single peptide bond, Pro72-Met73.
DISCUSSION
In the present study, we prepared thirteen SSI mutants, in which amino acid residues at various positions from 64 to 74 were altered (replaced or deleted), and examined the effects of these alterations on the inhibitory activity toward SGMP II in order to elucidate the specific locus on an SSI molecule responsible to the interaction with this enzyme. In most of the mutants, the strength of inhibitory activity toward SGMP II was changed to a notable extent, as shown in Table I . For example, replacement at position 73, which corresponds to the PI site for subtilisin, affected the affinity for SGMP II in various manners. Replacement of Met70 by smaller residues such as Gly and Ala markedly enhanced the affinity for SGMP II. Steric hindrance by a bulky residue at this position has been already observed in the interaction of SSI(M73K) with trypsin and lysylendopeptidase (18) . Deletion of Thr64 and/or Gly66 also resulted in a large increase in the affinity, suggesting that these residues on the "flexible loop" (11) of SSI may tend to obstruct the interaction with SGMP II. Similar results have been obtained in the interaction of SSI(M73K) with trypsin, but in this case the double deletion at Thr64 and Gly66 converted SSI into a temporary inhibitor of trypsin (28) . The inhibition of SGMP II by SSI(T64J, G66zJ) was not temporary.
While the three-dimensional structures of mutated SSIs in the free state are not known yet, those of SSI(M73K) and SSI (M73K, M70G) in the complexes with subtilisin BPN' (29) or bovine trypsin (30) have been analyzed by X-ray crystallography. The results indicate that the overall structures of these mutants do not differ from that of wild-type SSI. Accordingly, notable conformational change may have not been induced in SSI, at least by the replacement mutations adopted in this study. It may be concluded, therefore, that some residues in the segment from Thr64 to Met73 are involved in the interaction of SSI with SGMP II. This conclusion is consistent with the previous observation that SGMP II and subtilisin BPN' interact with SSI in a competitive manner (16) . Our strategy, however, does not exclude the possibility that some regions other than this segment also participate in the binding with SGMP II.
It is worthwhile to recall that SGMP II is inhibited by API-2c' and PS more strongly than by SSI: the K { values reported are 41 nM for SSI, 1.3 nM for API-2c', and 74 pM for PS (16) . The primary structures of API-2c' and PS are 90 and 69% homologous, respectively, to that of SSI (6, 7) , and the tertiary structure of PS is very similar to that of SSI (32) . The reactive sites of API-2c' for subtilisin BPN' and of PS for bovine trypsin have been identified as Met73-Ile74 (32) and Lys73-Gln74 (33), respectively. The alignment of the amino acid sequences around these sites is shown in Fig. 3 . We may assume that SGMP II also interacts with API-2c' and PS in these segments as in the case of SSI. Only three amino acid substitutions are present in this region between SSI and API-2c'. We can see in Table   Vol I an unfavorable effect of the carboxyl group at position 68 on the SGMP E-SSI interaction. API-2c' has Gly without a negative charge at this position. Thus, the 30 times higher affinity in the SGMP EI-API-2c' complex could be mostly explained by this substitution. On the other hand, eightresidue substitution is present between SSI and PS in this region. An explanation of the more than 500 times higher affinity of PS than SSI for SGMP II may require additional mutation studies.
The mechanism of interaction between serine proteases and protein protease inhibitors has been extensively studied (34) . The reactive site of SSI for subtilisin BPN' and for a-chymotrypsin was proved to be Met73-Val74 by preparing the "modified" SSI, in which this peptide bond was specifically split by the latter enzyme, and by regenerating the lost bond by the action of the former enzyme (10) . On the other hand, little is known about the reactive site of protein metallo-endopeptidase inhibitors, except for SMPI from Streptomyces nigrescens. The reactive site of SMPI for thermolysin has been assumed to be Cys64-Val65 in view of the selective cleavage of the bond by this enzyme (8) . Our first attempt to assign the reactive site of SSI for SGMP II by a similar approach was unsuccessful, because the wild-type SSI was not cleaved by SGMP II at a specific site. To overcome this problem, we used a mutated SSI in which the disulfide bridge, present near the reactive site for subtilisin BPN' in the wild-type, had been eliminated. We considered that this mutant, SSI(C71S, C101S), could be used for the assignment of the reactive site for SGMP II for the following two reasons, (i) It exhibits almost the same inhibitory activity toward SGMP II as that of wild-type SSI. (ii) Subtilisin BPN' (27), a-chymotrypsin, and SGPB (this study) cleave this mutant initially at the Met73-Val74 bond which has been identified as the reactive site for these enzymes in wild-type SSI. An analogous strategy using a disulfide-eliminated inhibitor has been adopted by Jering and Tschesche to prepare the "modified" inhibitor from Kunitz pancreatic trypsin inhibitor, which is rather resistant to proteolytic action (36) .
As expected, SSI(C7lS, C101S) was found to be selectively cleaved by SGMP II. The site was Pro72-Met73. On an illustration of the SSI monomer in Fig. 4 , arrows indicate this site and that cleaved by the serine proteases mentioned above. The Pro72-Met73 bond is situated in the supposed interacting area of SSI with SGMP II (16) . At present, we have no idea of the requirements for the reactive site of protein metallo-endopeptidase inhibitors. However, if the proposal by Laskowski, Jr. and Sealock (37) for the reactive site of "serine protease" inhibitors is applicable to that of SSI as a "metallo-endopeptidase" inhibitor, the Pro72-Met73 bond may be assigned as the reactive site for SGMP II. Thus, SSI has overlapping reactive sites for serine proteases and a metallo-endopep- tidase, SGMP H, on the Pro72-Met73-Val74 segment. Identification of suitable reaction conditions to regenerate the peptide bond cleaved by SGMP II and, of course, analysis of the complex by X-ray crystallography will be required for confirmation of the Pro72-Met73 bond as the reactive site of SSI for the Streptomyces metallo-endopeptidase.
